BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/04/22
BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line GuidancePRNewsWire • 08/03/22
These eight health-care stocks can keep you invested in the market with less worryMarket Watch • 08/02/22
BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ETPRNewsWire • 07/20/22
BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster PresentationsPRNewsWire • 07/11/22
5 Sizzling Goldman Sachs Conviction List Stocks to Buy Now With 100% or More Upside Potential24/7 Wall Street • 06/29/22
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia APRNewsWire • 06/24/22
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not ClosedPRNewsWire • 06/21/22
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in AtlantaPRNewsWire • 06/13/22
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia APRNewsWire • 05/31/22
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 05/27/22
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth PlansPRNewsWire • 05/05/22
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform PresentationsPRNewsWire • 05/05/22
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amETPRNewsWire • 05/04/22
BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22